If you have rotated through different clinical settings — or read international guidelines during revision — you have probably encountered three different cardiovascular risk calculators and wondered which one you should actually be using. QRISK3. ASCVD Pooled Cohort Equations. SCORE2/SCORE2-OP. They all estimate cardiovascular risk. They give different numbers for the same patient. And they lead to different treatment decisions.
The answer for UK doctors is straightforward: use QRISK3. But understanding why — and what goes wrong when you use the wrong tool — is both clinically important and directly tested in postgraduate exams.
The Three Calculators — What Each One Is
QRISK3 is the UK standard. Developed by researchers at the University of Nottingham using the QResearch primary care database (millions of UK patients). Endorsed by NICE (CG181). Estimates 10-year cardiovascular disease risk for patients aged 25-84 without pre-existing CVD. Includes variables specific to UK populations: Townsend deprivation score, UK ethnicity categories, SLE, atypical antipsychotics, severe mental illness, migraine, erectile dysfunction, corticosteroids.
ASCVD Pooled Cohort Equations (PCE) is the US standard. Developed by the ACC/AHA using pooled US cohort studies. Estimates 10-year atherosclerotic cardiovascular disease risk for patients aged 40-79. Used in the ACC/AHA 2018/2019 guidelines. Includes race as Black/White/Other — different categories from UK ethnicity classifications.
SCORE2 / SCORE2-OP is the European standard. Developed by the European Society of Cardiology. SCORE2 covers ages 40-69; SCORE2-OP covers ages 70+. Estimates 10-year fatal and non-fatal CVD risk. Calibrated to four risk regions (low, moderate, high, very high) across Europe. The UK is classified as a "low risk" country.
The Threshold Differences — Why They Matter
NICE (using QRISK3): Offer statin therapy when the 10-year CVD risk is ≥10%. The specific recommendation is atorvastatin 20mg after a shared decision-making conversation that includes discussion of benefits, risks, and lifestyle modification (NICE CG181).
ACC/AHA (using ASCVD PCE): Consider statin therapy when the 10-year ASCVD risk is ≥7.5%. The recommendation includes a "risk discussion" at 5.0-7.5% and a stronger recommendation at ≥20%. High-intensity statin therapy (atorvastatin 40-80mg or rosuvastatin 20-40mg) is recommended for high-risk patients.
ESC (using SCORE2): Treatment thresholds are age-dependent and region-dependent. For a "low risk" country like the UK, the ESC guidelines suggest treatment consideration at different thresholds for different age groups — more complex than a single cutoff.
The practical consequence: a patient with a 10-year risk of 8.5% qualifies for statin discussion under ACC/AHA (≥7.5%) but does not yet meet the NICE threshold (≥10%). Using the ASCVD calculator in UK practice could lead to premature statin initiation — or, conversely, using QRISK3 for a US patient could delay appropriate treatment.
Why Using the Wrong Calculator Is Not Just Inaccurate — It Is Clinically Harmful
The calculators are not interchangeable. They use different input variables (QRISK3 includes Townsend deprivation; ASCVD does not). They were validated on different populations (UK primary care vs US cohort studies vs European registries). They estimate slightly different outcomes (QRISK3 estimates total CVD events; ASCVD estimates atherosclerotic CVD events; SCORE2 estimates fatal and non-fatal CVD).
For a UK GP, QRISK3 is the correct tool because it was validated on the population you are treating, uses the variables available in UK primary care records (including deprivation, which is a strong independent risk factor in UK populations), and its treatment thresholds align with NICE — the guideline framework your practice, your QOF targets, and your exam all reference.
What This Means for Exams
The MRCGP AKT expects you to use QRISK3 and apply the NICE CG181 10% threshold. An AKT question presenting a patient's cardiovascular risk factors and asking "what is the most appropriate next step?" expects the answer based on QRISK3 and NICE — not ASCVD and ACC/AHA.
The UKMLA tests UK-specific clinical management. Using ASCVD thresholds in your reasoning will produce wrong answers on questions about statin initiation, cardiovascular risk discussion, and primary prevention.
iatroX Calculators provides QRISK3 with NICE CG181-referenced interpretation, the ASCVD calculator with ACC/AHA-referenced interpretation (for comparison or international context), and SCORE2 with ESC-referenced interpretation. Each calculator clearly states which guideline it aligns with and which jurisdiction it applies to — so you always know which threshold you are applying and why.
The Bottom Line
If you practise in the UK: use QRISK3 on iatroX. Apply the NICE CG181 10% threshold. Offer atorvastatin 20mg after shared decision-making for patients at or above threshold.
If you are comparing international guidelines for academic purposes or treating patients from different healthcare systems: understand all three tools and their threshold differences — but default to the calculator validated for your practice population.
Available at iatrox.com/calculators.